NCT01262118 - Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

February 29, 2012

Conditions

Rheumatoid Arthritis

Interventions

DRUG

CP-690,550 (tasocitinib)

CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis

Trial Locations (11)

Pfizer Investigational Site, Budapest

Pfizer Investigational Site, Balatonfüred

Pfizer Investigational Site, Daytona Beach

Pfizer Investigational Site, Ormond Beach

Pfizer Investigational Site, South Miami

Pfizer Investigational Site, Anniston

Pfizer Investigational Site, Anniston

Pfizer Investigational Site, Bingham Farms

Pfizer Investigational Site, Little Rock

Pfizer Investigational Site, Dallas

Pfizer Investigational Site, Los Angeles